doxepin has been researched along with Fatigue in 3 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain." | 9.30 | Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. ( Curtis, A; Ko, SJ; Le-Rademacher, JG; Leenstra, JL; Loprinzi, CL; Martenson, JA; Miller, RC; Novotny, PJ; Qin, R; Reiter, PL; Rine, G; Singh, AK; Sio, TT; Tan, AD, 2019) |
| "The purpose of this research was to determine if histamine, acting on brain H1 receptors, influences changes in feelings of energy and fatigue or cognitive test performance after acute exercise." | 9.22 | The effect of histamine on changes in mental energy and fatigue after a single bout of exercise. ( Loy, BD; O'Connor, PJ, 2016) |
| "To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain." | 5.30 | Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. ( Curtis, A; Ko, SJ; Le-Rademacher, JG; Leenstra, JL; Loprinzi, CL; Martenson, JA; Miller, RC; Novotny, PJ; Qin, R; Reiter, PL; Rine, G; Singh, AK; Sio, TT; Tan, AD, 2019) |
| "The purpose of this research was to determine if histamine, acting on brain H1 receptors, influences changes in feelings of energy and fatigue or cognitive test performance after acute exercise." | 5.22 | The effect of histamine on changes in mental energy and fatigue after a single bout of exercise. ( Loy, BD; O'Connor, PJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sio, TT | 1 |
| Le-Rademacher, JG | 1 |
| Leenstra, JL | 1 |
| Loprinzi, CL | 1 |
| Rine, G | 1 |
| Curtis, A | 1 |
| Singh, AK | 1 |
| Martenson, JA | 1 |
| Novotny, PJ | 1 |
| Tan, AD | 1 |
| Qin, R | 1 |
| Ko, SJ | 1 |
| Reiter, PL | 1 |
| Miller, RC | 1 |
| Loy, BD | 1 |
| O'Connor, PJ | 1 |
| Goldberg, HL | 1 |
| Finnerty, RJ | 1 |
| Cole, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy[NCT02229539] | Phase 3 | 275 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total pain reduction (mouth and throat) was measured by the numerical analogue scale of mouth pain on a scale of 0 to 10, with 0=no pain and 10=worst pain in the questionnaires taken at baseline, and 5, 15, 30, 60, 120, 240 minutes after assigned treatment for doxepin or DLA vs. placebo. The total pain reduction was calculated by the (average of mouth and throat) area under the curve (AUC) adjusting for baseline, with time scale (baseline, 5, 15, 30, 60, 120 and 240 minutes post treatment) replaced by a numerical scale of 0, 1, 2, 3, 4, 5 and 6 respectively. The AUC was prorated when there are terminal missing data. If the missing data were intermittent, simple imputation by trapezoidal rules were applied to calculate the AUC. If a patient cancelled, was missing baseline data, or only provided baseline data, he/she was excluded from the statistical analysis. (NCT02229539)
Timeframe: Baseline, 5, 15, 30, 60, 120, 240 minutes post treatment
| Intervention | units on a scale*time scale (Mean) |
|---|---|
| Doxepin | 11.9 |
| DLA (Diphenhydramine, Lidocaine and Antacid) | 11.7 |
| Placebo | 8.7 |
3 trials available for doxepin and Fatigue